Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board?
Illumina, Inc. recently expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., an independent director and Eli Lilly’s Chief Scientific and Product Officer, effective June 16, 2026. Bringing in a senior R&...
Strong Bullish
88.6